Q1 2021 13F Holders as of 3/31/2021
-
Type / Class
-
Equity / Common Stock, par value $0.0001 per share
-
Shares outstanding
-
98.6M
-
Number of holders
-
66
-
Total 13F shares, excl. options
-
27.7M
-
Shares change
-
+3.25M
-
Total reported value, excl. options
-
$1.21B
-
Value change
-
+$139M
-
Number of buys
-
38
-
Number of sells
-
-35
-
Price
-
$43.63
Significant Holders of ARS Pharmaceuticals, Inc. - Common Stock, par value $0.0001 per share (SPRY) as of Q1 2021
89 filings reported holding SPRY - ARS Pharmaceuticals, Inc. - Common Stock, par value $0.0001 per share as of Q1 2021.
ARS Pharmaceuticals, Inc. - Common Stock, par value $0.0001 per share (SPRY) has 66 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 27.7M shares
of 98.6M outstanding shares and own 28.09% of the company stock.
Largest 10 shareholders include ORBIMED ADVISORS LLC (8.74M shares), FMR LLC (4.83M shares), EcoR1 Capital, LLC (2.53M shares), RA CAPITAL MANAGEMENT, L.P. (1.74M shares), BOXER CAPITAL, LLC (1.68M shares), BlackRock Inc. (1.22M shares), VANGUARD GROUP INC (1.09M shares), Nantahala Capital Management, LLC (992K shares), Cormorant Asset Management, LP (500K shares), and AMERIPRISE FINANCIAL INC (425K shares).
This table shows the top 66 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.